Potential role for anti-angiogenic therapy in abdominal aortic aneurysms

European Journal of Clinical Investigation

Volumn 43, Issue 7, 2013, Pages 758-765

  Vijaynagar, Badri ^a,b   Bown, Matt J ^a,b   Sayers, Robert D ^a,b   Choke, Edward ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Abdominal aortic aneurysm; Angiogenesis; Anti angiogenic therapy; Medical therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; AZITHROMYCIN; CATHEPSIN; CHYMASE; CYCLOOXYGENASE 2; CYSTEINE PROTEINASE; DOXYCYCLINE; EZETIMIBE; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROPRANOLOL; PROSTAGLANDIN E2; RESVERATROL; ROXITHROMYCIN; SIMVASTATIN; TRANILAST; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ABDOMINAL AORTA ANEURYSM; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTIPROLIFERATIVE ACTIVITY; AORTA WALL; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; BASEMENT MEMBRANE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; CROHN DISEASE; DIABETES MELLITUS; DISEASE COURSE; EMBRYO DEVELOPMENT; ENDOTHELIAL PROGENITOR CELL; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATORY INFILTRATE; LIFE EXPECTANCY; MICROVASCULATURE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; TISSUE DIFFERENTIATION; VASODILATATION; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS;

EID: 84878915614     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12103     Document Type: Article

References (55)

1. Cosford PA, LengGC, Thomas J. Screening for abdominal aortic aneurysm. Cochrane Database Syst Rev 2007;Art.No CD002945/14651858.CD002945.pub2.
2. Bown MJ, Sutton AJ, Bell PR, Sayers RD. A meta-analysis of 50 years of ruptured abdominal aortic aneurysm repair. Br J Surg 2002;89:714-30.
3. UK Small Aneurysm Trial participants. Final 12-year follow-up surgery versus surveillance in the UK Small Aneurysm Trial. Br J Surg 2007;94:702-8.
4. Miyake T, Morishita R. Pharmacological treatment of abdominal aortic aneurysm. Cardiovasc Res. 2009; 83:436-43.
5. Dodd BR, Spence RA. Doxycycline inhibition of abdominal aortic aneurysm growth: a systematic review of the literature. Curr Vasc Pharmacol. 2011; 9:471-8.
6. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomised clinical trial. Ann N Y Acad Sci 1999;878:159-78.
7. Fong IW, Chiu B, Viira E et al. Can an antibiotic (macrolide) prevent Chlamydia pneumoniae- induced atherosclerosis in a rabbit model? Clin Diagn Lab Immunol 1999;6:891-4.
8. Mosorin M, Juvonen J, Biancari F et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001;34:606-10.
9. Dawson JA, Choke E, Loftus IM et al. A randomised placebo-controlled double-blind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2011;41:28-35.
10. Karlsson L, Gnarpe J, Bergqvist D et al. The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms - a prospective randomized double-blind trial. J Vasc Surg 2009;50:23-9.
11. Lindholt JS, Sorensen HT, Michel JB et al. Low-dose aspirin may prevent growth and later surgical repair of medium-sized abdominal aortic aneurysms. Vasc Endovascular Surg 2008;42:329-34.
12. Lindholt JS, Henneberg EW, Juul S, Fasting H. Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angiol 1999;18:52-7.
13. Vammen S, Lindholt JS, Ostergaard L et al. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 2001;88:1066-72.
14. Propranolol Aneurysm Trial Investigators. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J Vasc Surg 2002;35:72-9.
15. Chapple KS, Parry DJ, McKenzie S et al. Cyclooxygenase-2 expression and its association with increased angiogenesis in human abdominal aortic aneurysms. Ann Vasc Surg 2007;21:61-6.
16. Choke E, Cockerill GW, Dawson J et al. Increased angiogenesis at the site of abdominal aortic aneurysm rupture. Ann N Y Acad Sci 2006;1085:315-9.
17. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.
18. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001;49:507-21.
19. Kajdaniuk D, Marek B, Foltyn W, Kos-KudlŁa B. Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology. Endokrynol Pol 2011;62:444-55.
20. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-70.
21. Wolinsky H, Glagov S. Nature of species differences in the medial distribution of vasa vasorum in mammals. Circulation Research. 1967;20:409-21.
22. Kobayashi M, Matsubara J, Matsushita M et al. Expression of angiogenesis and angiogenic factors in human aortic vascular disease. J Surg Res 2002;106:239-45.
23. Thompson MM, Jones L, Nasim A et al. Angiogenesis in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1996;11:464-9.
24. Choke E, Cockerill GW, Dawson J et al. Vascular endothelial growth factor enhances angiotensin II-induced aneurysm formation in apolipoprotein E-deficient mice. J Vasc Surg 2010;52:159-66.
25. Holmes DR, Liao S, Parks WC et al. Medial neovascularization in abdominal aortic aneurysms: a histopathologic marker of aneurysmal degeneration with pathophysiologic implications. J Vasc Surg 1995;21:761-71; discussion 771-2.
26. Choke E, Thompson MM, Dawson J et al. Abdominal aortic aneurysm rupture is associated with increased medial neovascularization and overexpression of proangiogenic cytokines. Arterioscler Thromb Vasc Biol 2006;26:2077-82.
27. Paik DC, Fu C, Bhattacharya J, Tilson MD. Ongoing angiogenesis in blood vessels of the abdominal aortic aneurysm. Exp Mol Med 2004;36:524-33.
28. Swedenborg J, Mäyränpää MI, Kovanen PT. Mast cells: important players in the orchestrated pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2011;31:734-40.
29. Choke E, Cockerill GW, Dawson J et al. Hypoxia at the site of abdominal aortic aneurysm rupture is not associated with increased lactate. Ann N Y Acad Sci 2006;1085:306-10.
30. Vorp DA, Lee PC, Wang DHJ et al. Association of intraluminal thrombus in abdominal aortic aneurysm with local hypoxia and wall weakening. J Vasc Surg 2001;34:291-9.
31. Sakuda H, Nakashima Y, Kuriyama S et al. Media conditioned by smooth muscle cells cultured in a variety of hypoxic environments stimulates in vitro angiogenesis. A relationship to transforming growth factor-beta 1. The. Am J Pathol 1992;141:1507-16.
32. Chiarugi V, Magnelli L, Chiarugi A, Gallo O. Hypoxia induces pivotal tumor angiogenesis control factors including p53, vascular endothelial growth factor and the NFkB-dependent inducible nitric oxide synthase and cyclooxygenase-2. J Cancer Res Clin Oncol 1999;125:525-8.
33. Knighton DR, Hunt TK, Scheuenstuhl H et al. Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science 1983;221:1283-5.
34. Yamagishi M, Higashikata T, Ishibashi H et al. Sustained upregulation of inflammatory chemokine and its receptor in aneurysmal and occlusive atherosclerotic disease: results from tissue analysis with cDNA macroarray and real-time reverse transcriptional polymerase chain reaction methods. Circ J 2005;69:1490-5.
35. Treska V, Kocova J, Boudova L et al. Inflammation in the wall of abdominal aortic aneurysm and its role in the symptomatology of aneurysm. Cytokines Cell Mol Ther 2002;7:91-7.
36. Rijbroek A, Moll FL et al. Inflammation of the abdominal aortic aneurysm wall. Eur J Vasc Surg 1994;8:41-6.
37. Middleton R, Lloyd GL, Bown MJ et al. The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. J Vasc Surg 2007;45:574-80.
38. Holmes DR, Wester W, Thompson RW et al. Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg 1997;25:810-5.
39. Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 2009;9:503-9.
40. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
41. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
42. Lainer DT, Brahn E. New antiangiogenic strategies for the treatment of proliferative synovitis. Expert Opin Investig Drugs 2005;14:1-17.
43. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
44. Hardy-Bessard AC, Delva R et al. Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France. Bull Cancer 2012;99:609-18.
45. Kaneko H, Anzai T, Takahashi T et al. Role of vascular endothelial growth factor-A in development of abdominal aortic aneurysm. Cardiovasc Res 2011;91:358-67.
46. Miwa K, Nakashima H, Aoki M et al. Inhibition of ets, an essential transcription factor for angiogenesis, to prevent the development of abdominal aortic aneurysm in a rat model. Gene Ther 2005;12:1109-18.
47. Sun J, Sukhova GK, Zhang J et al. Cathepsin L activity is essential to elastase perfusion-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol 2011;31:2500-8.
48. Sun J, Sukhova GK, Zhang J et al. Cathepsin K deficiency reduces elastase perfusion-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol 2012;32:15-23.
49. Veillard NR, Braunersreuther V, Arnaud C. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranylisoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006;188:51-8.
50. Zhang Y, Naggar JC, Welzig CM et al. Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol 2009;29:1764-71.
51. Dunne JA, Bailey MA, Griffin KJ et al. Statins: The Holy Grail of Abdominal Aortic Aneurysm (AAA) Growth Attenuation? A systematic review of the literature Curr Vasc Pharmacol 2012.
52. Palmieri D, Pane B, Barisione C et al. Resveratrol counteracts systemic and local inflammation involved in early abdominal aortic aneurysm development. J Surg Res 2011;171:e237-46.
53. Tsuruda T, Kato J, Hatakeyama K et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res 2008;102:1368-77.
54. Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: angiogenesis, tissue remodeling and immune-modulation. Biochim Biophys Acta 2009;1796:19-26.
55. Saraff K, Babamusta F, Cassis LA, Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003;23:1621-6.